Research Advances on Small Molecule Targets for Tumor Immunotherapy

After decades of unremitting efforts, tumor immunotherapy has made significant progress. For patients with advanced cancer, significant clinical benefit has been achieved by blocking the T-cell immune checkpoint PD-1 or CTLA-4 receptor, significantly extending patients' survival. However, in the unselected population, the overall efficiency is still less than 20%, so it is necessary to explore new immunotherapeutics and treatment models. Small molecule-based immunotherapeutic methods have significant advantages in pharmacokinetics and drug utility, showing potential in early studies. This article will review the current status of small-molecule immunotherapy for tumors, in order to find more precise targets for immunotherapy.